Unmet needs for GI diseases like celiac

John Temperato, CEO of RDD Pharma and what will be 9 Meters Biopharma, discusses GI diseases, current treatments, why there are still unmet needs for diseases like celiac and others, and what’s on the horizon.  Through the RDD/Innovate merger, 9 Meters will have larazotide, the first-ever drug candidate to enter Phase 3 registration trials for celiac disease.

John is an industry veteran with a wealth of gastrointestinal (GI) focused experience in both the operational and commercial aspects of the business.  Prior to joining RDD, John held various leadership roles including most notably U.S. President & Chief Operating Officer with Atlantic Healthcare, President & Chief Operating Officer/Chief Commercial Officer with Melinta Therapeutics, and Senior Vice President of Sales and Managed Markets with Salix Pharmaceuticals. Notably, at Salix Pharmaceuticals (Salix), Mr. Temperato played a critical role in the successful commercialization and growth of their broad GI portfolio and executed over ten launches during his tenure at the company driving the growth of company revenues from $119 million in 2004 to $2 billion in 2015. Across his career, John has been instrumental in defining and executing capital-efficient go-to-market strategies, business development strategy and overseeing the commercialization and life-cycle management for small molecules, devices, and biologics. Additionally, he has developed strategies for reimbursement and external healthcare policy.